Allscripts Healthcare Solutions, Inc., together with its subsidiaries, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates in two segments: The Core Clinical and Financial Solutions; and The Data, Analytics and Care Coordination. The Core Clinical and Financial Solutions segment provides software applications for patient engagement, and integrated clinical and financial management solutions, which primarily include EHR-related software; and financial and practice management software solutions, as well as related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Data, Analytics and Care Coordination segment offers practice reimbursement, and payer and life sciences solutions, which are primarily targeted at physician practices, payers, life sciences companies, and other healthcare stakeholders. Its solutions enable clients to transition, analyze, and coordinate care and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments, health systems, health plans, life-sciences companies, retail clinics, retail pharmacies, pharmacy benefit managers, insurance companies, and employer wellness clinics, as well as post-acute organizations, such as home health and hospice agencies. Allscripts Healthcare Solutions, Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
IPO Year:
Exchange: NASDAQ
Website: allscripts.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/19/2024 | $15.00 → $10.00 | Buy → Hold | Deutsche Bank |
| 1/3/2024 | $11.00 | Equal Weight | Barclays |
| 7/6/2023 | Buy → Hold | Argus | |
| 4/12/2023 | $13.00 | Equal-Weight | Stephens |
| 2/1/2023 | $17.00 → $18.50 | Overweight → Neutral | Piper Sandler |
| 12/7/2022 | $26.00 | Hold → Buy | Argus |
| 11/9/2022 | $22.00 → $23.00 | Neutral → Buy | Goldman |
| 11/4/2022 | $17.00 | Overweight | Piper Sandler |
| 9/16/2022 | Sector Weight | KeyBanc Capital Markets | |
| 7/12/2022 | $21.00 | Neutral | Goldman |
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13D - Veradigm Inc. (0001124804) (Subject)
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13G/A - Veradigm Inc. (0001124804) (Subject)
SC 13G - Veradigm Inc. (0001124804) (Subject)
SC 13G - Veradigm Inc. (0001124804) (Subject)
Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve
Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that its Board of Directors (the "Board") has approved an amendment to extend the Company's existing Stockholder Rights Plan (the "Rights Plan"). The Rights Plan, adopted on February 26, 2024, was due to expire on February 26, 2025. Under the terms of the amendment to the Rights Plan, the scheduled expiration date of the Rights Plan has been extended to August 20, 2025. To reflect changes in the price of Company common stock since February 26, 2024, the amendment to the Rights Plan also updates the exercise price for the purchase of rights under the Rights Plan from $50.00 to $32.00. The
With the introduction of seven new disease-specific registry datasets, Veradigm is enabling deep, targeted research to drive innovation and enhance real-world clinical insights Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today the launch of its disease-specific cardiometabolic Clinical Data Registry datasets, which contain de-identified information about patients' health and care for a specific condition or disease. These datasets provide researchers with access to specialty, Natural Language Processing (NLP)-enhanced real-world data to advance the understanding of patient insights and clinical details to support research throughout the d
EHR solution receives top rankings for ease of navigation, telehealth integration and client experience, amplifying company's commitment to supporting ambulatory provider practices Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book Research, a leader in healthcare industry insights, has ranked Veradigm EHR first for both Ambulatory EHR Family Practice and Ambulatory EHR Primary Care General Practice in its 2025 Top-Rated EHR Vendors by Specialty. The prestigious rating solidifies Veradigm's commitment to designing technology for providers, empowering informed patient care, streamlined workflows and enhanced operational ef
Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti
Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced that on January 28, 2025, Beth Altman stepped down from the Company's Board of Directors ("Board") due to health reasons. Her decision to resign was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Ms. Altman's resignation has no impact on the Company's ongoing restatement of its 2022 financial statements. Altman has been a valued advisor since 2020 and, as Audit Committee Chair, has been instrumental in helping the Company navigate a challenging period. Following Altman's resignation, the Board appointed Greg
Veradigm Network EHR (VNEHR) Data includes over 154M unique patients nationally, transforming research capabilities and advancing patient care Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced the integration of two new datasets to expand the depth and breadth of Veradigm Network EHR (VNEHR) Data, one of the nation's most comprehensive ambulatory electronic health record (EHR) databases. The database enrichment includes social determinants of health (SDoH) and mortality data, giving researchers new insights to tackle health disparities, enhance real-world evidence (RWE) studies, improve care, and offer strategic and operational benefits
The AI-powered addition to the Veradigm Network can reduce documentation time, increase operational efficiency, and enhance patient care Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today the launch of Veradigm Ambient Scribe, an artificial intelligence (AI)-enabled ambient scribe platform designed to ease the documentation burden for healthcare providers. By adding Veradigm Ambient Scribe to the Veradigm Network, Veradigm advances its efforts to provide insightful solutions that drive value for healthcare providers. The solution helps to alleviate the daily administrative burden while enhancing provider-patient interactions. Veradigm A
Leveraging the Veradigm Network to bring real-time insights directly into healthcare provider workflows on behalf of Payers Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, today announced an enhanced strategic collaboration with Insiteflow, an electronic health record (EHR) decision workflow platform. This effort expands Veradigm Payer Insights (VPI) beyond the Veradigm EHR footprint into additional EHRs technologies. Together, Veradigm and Insiteflow are placing actionable insights on behalf of Payers at the point of care across multiple EHR platforms —including Veradigm EHR and Practice Fusion. VPI is now offered to additional EHR platforms, includi
NLP-enhanced data from over 154 million patient records facilitates innovation in real-world evidence research via the Veradigm Network Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today the complete integration of advanced natural language processing (NLP) into its electronic health record (EHR) dataset. This integration enhances access to valuable insights from unstructured EHR data and combines it with structured data to create regulatory-grade, real-world data (RWD) that's purpose-built for research. Veradigm Network EHR Data is sourced from over 154 million unique patient records and is one of the most comprehensive ambulatory databa
4/A - Veradigm Inc. (0001124804) (Issuer)
4 - Veradigm Inc. (0001124804) (Issuer)
Engaged an Independent Strategic Advisor to Refine Go-Forward Plan Company to Provide a Financial and Business Update in March Veradigm® (OTC:MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value. Review of Strategic Alternatives Throughout the review process, the Board, in collaboration with its financial and legal advisors, evaluated potential strategic opportunities, including a possible sale of the Company. Following the May 2024 public announcement of the process, the Company entered into confidenti
Veradigm®, Inc. (NASDAQ:MDRX), will report its financial results for the three and twelve months ended December 31, 2022 after the close of the regular stock market hours on Wednesday, March 1, 2023. Veradigm management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Fourth-Quarter 2022 Financial Results Call Details To listen to the conference call, participants may log onto the Veradigm Investor Relations website. Participants also may access the conference call by dialing 877-269-7756 or 201-689-7817 and requesting Conference ID # 13735356. A replay of the call will be available for a period of a year on the Veradi
Veradigm Inc. (NASDAQ:MDRX), formerly Allscripts Healthcare Solutions, Inc., announced today that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250 million of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250 million of common stock which was almost fully utilized during 2022. In the fourth quarter of 2022 Veradigm repurchased $57 million of its common stock, bringing its full year total to $234 million. The company also introduced initial financial guidance for Fiscal 2023 as follows: Revenue is expected between $640 million and $660
Third quarter consolidated revenue of $152 million Third quarter consolidated operating profit up over 30% year-over-year Generated $42 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and nine months ended September 30, 2022. Third quarter 2022 Veradigm revenue was $145 million compared with $137 million in the third quarter of 2021. On a consolidated Allscripts basis third quarter 2022 revenue was $152 million compared with $145 million in the third quarter of 2021. On a GAAP basis, Veradigm income from operations was $28 million in the third quarter of 202
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended September 30, 2022 after the close of stock market hours on Thursday, November 3, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Third-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, November 3, 2022. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts I
Second quarter bookings of $107 million and $172 million year-to-date, up 10% from the first half of 2021 Generated $42 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three and six months ended June 30, 2022. Second quarter 2022 Veradigm revenue was $145 million compared with $133 million in the second quarter of 2021. On a consolidated Allscripts basis second quarter 2022 revenue was $151 million compared with $141 million in the second quarter of 2021. In the second quarter, Allscripts completed the sale of its Hospital and Large Physician Practices Segment. The
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended June 30, 2022 after the close of stock market hours on Thursday, August 4, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. Second-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, August 4, 2022. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts Investor
First quarter GAAP diluted EPS of $0.17; non-GAAP diluted EPS of $0.13 Closed the sale of Hospital & Large Physician Practices business segment to Constellation Software Generated $35 million of cash flow from continuing operations in the quarter Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) (Allscripts) announced its financial results for the three months ended March 31, 2022. First quarter 2022 Veradigm revenue was $136 million compared with $126 million in the first quarter of 2021. On a consolidated Allscripts basis first quarter 2022 revenue was $143 million compared with $134 million in the first quarter of 2021. On a GAAP basis in the first quarter of 2022, Veradigm in
Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX) will report its financial results for the three months ended March 31, 2022 after the close of stock market hours on Thursday, May 5, 2022. Allscripts management plans to host a conference call and webcast to discuss the company's earnings at 4:30 p.m. Eastern Time that same day. First-Quarter 2022 Financial Results Call Details The Allscripts earnings announcement will be distributed immediately after the close of regular stock market hours on Thursday, May 5, 2022. The announcement will also be available at Allscripts investor relations website. To listen to the conference call, participants may log onto the Allscripts Investor Relati
Allscripts Healthcare Solutions (NASDAQ:MDRX) ("Allscripts") announced today that it has reached an agreement with Constellation Software Inc. (TSX:CSU), through its wholly-owned subsidiary N. Harris Computer Corporation ("Harris"), to sell Harris the net assets of Allscripts Hospitals and Large Physician Practices business segment. The Hospitals and Large Physician Practices business segment includes the Sunrise™, Paragon®, Allscripts TouchWorks®, Allscripts® Opal, STAR™, HealthQuest™ and dbMotion™ solutions. The assets of Allscripts Veradigm business segment are not included in this transaction and will continue to be owned by Allscripts going forward. "The medical industry we faithfully
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
NT 10-Q - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
NT 10-Q - Veradigm Inc. (0001124804) (Filer)
8-K - Veradigm Inc. (0001124804) (Filer)
Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve
NEW YORK, Feb. 28, 2024 /PRNewswire/ -- Sprinklr Inc. (NYSE:CXM) will replace Veradigm Inc. (NASD:MDRX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, March 4. Veradigm will be suspended from the Nasdaq Stock Market on February 29 due to non-compliance with NASDAQ listing rules and is no longer eligible for continued inclusion in the S&P SmallCap 600. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector March 4, 2024 S&P SmallCap 600 Addition Sprinklr CXM Information Technology March 4, 2024 S&P SmallCap 600 Deletion Veradigm MDRX Hea
Sales and Operational Veteran Brings Additional Global Business Experience and Healthcare Technology Expertise to Board Omnicell, Inc. (NASDAQ:OMCL) ("Omnicell" or the "Company"), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company's Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company's Board at Omnicell's 2024 annual meeting of stockholders (the "2024 annual meeting") and e
Veradigm Inc. (NASDAQ:MDRX), a leading provider of healthcare data and technology solutions announced today the acquisition of Koha Health, a full-service revenue cycle management (RCM) company. With this acquisition, Veradigm further adds to its depth of offerings and expertise as a leading provider of revenue cycle services in the ambulatory healthcare market. "Today's announcement represents an exciting opportunity for Veradigm to scale our revenue cycle services portfolio by leveraging additional capabilities and subject matter expertise to better serve the needs of the market," said Tom Langan, President, and Chief Commercial Officer at Veradigm. This acquisition brings additional
NEW YORK, Dec. 08, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds shareholders that a complaint has been filed on behalf of purchasers of the common stock of Veradigm Inc ("Veradigm" or the "Company") (NASDAQ:MDRX), a healthcare technology company, between February 26, 2021 and June 13, 2023, inclusive (the "Class Period"). Click Here to Join Investigation. If you acquired Veradigm common stock and would like to discuss this case, please click here. You may also contact us by emailing [email protected] or calling (646) 315-9003. If you are a member of the proposed Class, you may move the court no later than January 22, 2024 to serve as a lead plaintiff for the purported
Greg Garrison Named Executive Chairman; Dr. Shih-Yin Ho Appointed Interim CEO; Lee Westerfield Appointed Interim CFO Veradigm Inc. (NASDAQ:MDRX) announced today that the Company's Board of Directors appointed current Chairman, Greg Garrison, as Executive Chairman, and current director, Dr. Shih-Yin ("Yin") Ho, as interim Chief Executive Officer. In addition, Lee Westerfield, who brings more than 25 years of experience as a senior financial executive, most recently serving as Chief Financial Officer at Clearsense, will be serving as Interim Chief Financial Officer. Chief Executive Officer Richard J. Poulton has resigned at the request of the Board from his role as CEO and has stepped dow
New solution to help providers digitally engage with patients, improving both practice efficiency and the patient experience Veradigm, Inc. (NASDAQ:MDRX), a leading provider of healthcare data and technology solutions announced today that it will now offer a new solution to help increase payment rates, accelerate time to payment, and reduce manual reconciliation time for healthcare provider practices. Veradigm Intelligent Payments is a bundle of financial communications and payment solutions and is now available within Veradigm Payerpath via a collaboration with RevSpring, a leading and respected provider of healthcare engagement and payment solutions. Veradigm Intelligent Payments offe
Healthcare IT Industry Expert Will Support the Firm's HCIT Strategy Thomas H. Lee Partners, L.P. ("THL"), a premier private equity firm investing in middle-market growth companies, today announced the appointment of Paul Black as a consultant for the firm's healthcare investment group. Black, who brings more than 25 years of experience leading companies in healthcare information technology ("Healthcare IT"), will support the team's efforts in identifying, sourcing, and growing investment opportunities across the healthcare market. "We are very pleased to welcome Paul to THL as a consultant for the firm's healthcare group," said Shahab Vagefi, Managing Director at THL. "THL has had a longs
WASHINGTON, Dec. 1, 2021 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Seth R. Frank has joined the company as Vice President, Investor Relations, effective immediately. Reporting to John Johnson, Evolent's Chief Financial Officer, Seth will lead Evolent's investor relations (IR) strategy and oversee its relationships with the investment community. "Seth provides a demonstrated track record of proactive, finance-driven leadership in health care investor relations to Evolent," said Evolent Health Chief Financial Officer John Johnson. "He brings long-ter
Deutsche Bank downgraded Veradigm from Buy to Hold and set a new price target of $10.00 from $15.00 previously
Barclays initiated coverage of Veradigm with a rating of Equal Weight and set a new price target of $11.00
Argus downgraded Veradigm from Buy to Hold
Stephens initiated coverage of Veradigm with a rating of Equal-Weight and set a new price target of $13.00
Piper Sandler downgraded Veradigm from Overweight to Neutral and set a new price target of $18.50 from $17.00 previously
Argus upgraded Allscripts Healthcare from Hold to Buy and set a new price target of $26.00
Goldman upgraded Allscripts Healthcare from Neutral to Buy and set a new price target of $23.00 from $22.00 previously
Piper Sandler resumed coverage of Allscripts Healthcare with a rating of Overweight and set a new price target of $17.00
KeyBanc Capital Markets initiated coverage of Allscripts Healthcare with a rating of Sector Weight
Goldman initiated coverage of Allscripts Healthcare with a rating of Neutral and set a new price target of $21.00